The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: A review

Anonymous, 1998, J Am Geriatr Soc, 46, 635, 10.1111/j.1532-5415.1998.tb01084.x Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Campbell, 1990, Lipid-derived autacoids: Eicosanoids and platelet-activating factor, 638 Campbell, 1996, Lipid-derived autacoids: Eicosanoids and platelet-activating factor, 601 Cannon, 2000, Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, Arthritis Rheum, 43, 978, 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0 Catella-Lawson Catella-Lawson, 1999, Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J Pharmacol Exp Ther, 289, 735 2002 Chan, 1999, Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor—pharmacological and biochemical profiles, J Pharmacol Exp Ther, 290, 551 Chang, 2001, Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial, Clin Ther, 23, 1446, 10.1016/S0149-2918(01)80119-3 Day, 2000, A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis, Arch Intern Med, 160, 1781, 10.1001/archinte.160.12.1781 Depré, 2000, Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans, Eur J Clin Pharmacol, 56, 167, 10.1007/s002280050736 DuBois, 1998, Cyclooxygenase in biology and disease, FASEB J, 12, 1063, 10.1096/fasebj.12.12.1063 Ehrich, 1999, Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model, Clin Pharmacol Ther, 65, 336, 10.1016/S0009-9236(99)70113-X Ehrich, 1999, Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib, J Rheumatol, 26, 2438 Gabriel, 1991, Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis, Ann Intern Med, 115, 787, 10.7326/0003-4819-115-10-787 Geba Geis, 1999, Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?, J Rheumatol, 26, 31 Goldstein, 1999, Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs, Gastroenterology, 116, A174 Greenberg, 2000, A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers, J Clin Pharmacol, 40, 1509, 10.1177/009127000004001224 Karim, 1997, SC-58635 (celecoxib): A highly selective inhibitor of cyclooxygenase-2—Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation, Pharm Res, 14, S617 Kömhoff, 1997, Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function, Am J Physiol, 272, F460 Konstam, 2001, Cardiovascular thrombotic events in controlled clinical trials of rofecoxib, Circulation, 104, r15, 10.1161/hc4401.100078 Laine, 1999, A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis, Gastroenterology, 117, 776, 10.1016/S0016-5085(99)70334-3 Langman, 1999, Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs, JAMA, 282, 1929, 10.1001/jama.282.20.1929 Lichtenstein, 1995, Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: The double-edged sword, Arthritis Rheum, 38, 5, 10.1002/art.1780380103 Malmstrom, 1999, Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial, Clin Ther, 21, 1653, 10.1016/S0149-2918(99)80045-9 McAdam, 1999, Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2, Proc Natl Acad Sci USA, 96, 272, 10.1073/pnas.96.1.272 Mengle-Gaw, 1997, A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor, Arthritis Rheum, 40, S93 Michalets, 1998, Update: Clinically significant cytochrome P-450 drug interactions, Pharmacotherapy, 18, 84, 10.1002/j.1875-9114.1998.tb03830.x Moreland, 1999, The use of analgesics in the management of pain in rheumatic diseases, Rheum Dis Clin North Am, 25, 153, 10.1016/S0889-857X(05)70059-4 Morrison, 1999, Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial, Clin Ther, 21, 943, 10.1016/S0149-2918(99)80016-2 Morrison, 1999, Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial, Obstet Gynecol, 94, 504, 10.1016/S0029-7844(99)00360-9 Mukherjee, 2001, Risk of cardiovascular events associated with selective COX-2 inhibitors, JAMA, 286, 954, 10.1001/jama.286.8.954 Porras, 2001, Single and multiple dose pharmacokinetics of rofecoxib in healthy subjects, Clin Pharm Ther, 67, 137 Prasit, 1999, The discovery of rofecoxib [MK 966, VIOXX, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, Bioorg Med Chem Lett, 9, 1773, 10.1016/S0960-894X(99)00288-7 Raskin, 1999, Gastrointestinal effects of nonsteroidal anti-inflammatory therapy, Am J Med, 106, 3S, 10.1016/S0002-9343(99)00112-6 Reicin, 2001, Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain, Am J Orthop, 30, 40 Reuben, 2000, Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery, Anesth Analg, 91, 1221 Rossat, 1999, Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects, Clin Pharmacol Ther, 66, 76, 10.1016/S0009-9236(99)70056-1 Schnitzer, 1999, The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis, Clin Ther, 21, 1688, 10.1016/S0149-2918(99)80048-4 Schwartz, 2000, Pharmacokinetics of rofecoxib in mild to moderate hepatic insufficiency, Clin Pharmacol Ther, 67 Schwartz, 2001, Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis, J Clin Pharmacol, 41, 1120, 10.1177/00912700122012616 Schwartz, 2001, Effect of rofecoxib, celecoxib, and naproxen on blood pressure (BP) in elderly volunteers, Am J Hypertens, 14, A177, 10.1016/S0895-7061(01)01606-5 Schwartz JI, Malice MP, Lasseter KC, Holmes GB, Gottesdiener KM, Brune K: Effect of rofecoxib, celecoxib, and naproxen on blood pressure and urinary sodium excretion in elderly volunteers [abstract]. 2001 European League Against Rheumatism (EULAR) 16th Congress, June 13-16, 2001, Prague, Czech Republic. Available at: http://www.eular.org/eular2001/AbstractsOnline.cfm. Accessed July 18, 2001 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study—a randomized controlled trial, JAMA, 284, 1247, 10.1001/jama.284.10.1247 Simon, 1998, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor, Arthritis Rheum, 41, 1591, 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J Simon, 1999, Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial, JAMA, 282, 1921, 10.1001/jama.282.20.1921 Smalley, 1995, Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons, Am J Epidemiol, 141, 539, 10.1093/oxfordjournals.aje.a117469 Swan, 2000, Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized controlled trial, Ann Intern Med, 133, 1, 10.7326/0003-4819-133-1-200007040-00002 Truitt KE, Guesens PP, DeTora LM, Zhao PL, Kress B: Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 25 and 50 mg in adult patients with rheumatoid arthritis (RA) [abstract]. 2001 European League Against Rheumatism (EULAR) 16th Congress, June 13-16, 2001, Prague, Czech Republic. Available at: http://www.eular.org/eular2001/AbstractsOnline.cfm. Accessed July 18, 2001 Vane, 1997, Mechanism of action of aspirin-like drugs, Semin Arthritis Rheum, 26, 2, 10.1016/S0049-0172(97)80046-7 2001 Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis, Proc Natl Acad Sci USA, 96, 7563, 10.1073/pnas.96.13.7563 Whelton, 2000, Effects of celecoxib and naproxen on renal function in the elderly, Arch Intern Med, 160, 1465, 10.1001/archinte.160.10.1465 White, 2001, Effects of the COX-2 specific inhibitor celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibition, Am J Hypertens, 14, A183, 10.1016/S0895-7061(01)01624-7